JPMorgan Diversified Return International Eqty ETF vs uniQure N.V. Ordinary Shares — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $382.97M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 3.9× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 121 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| JPIN | QURE | |
|---|---|---|
Market Cap | $382.97M | $1.48B |
Volume | 1,797 | 2,488,780 |
52-Week High | $77.80 | $70.59 |
52-Week Low | $65.86 | $9.03 |
Typical Hold Time | 121 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.52, up 0.65% today. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though the RSI suggests potential oversold conditions. The ETF provides broad exposure to international large-cap value stocks. A dividend of $0.51 is scheduled for payment in September 2026.
The outlook is cautious due to strong bearish technical signals. The primary opportunity lies in the ETF's international diversification and value focus, but risks include global market volatility and the current negative momentum. Investors should weigh the oversold RSI against the dominant sell signals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →